An Open-Label, Multi-Centre, Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of 2-Week Treatment with Inhaled AZD7594 in Adolescents (12 to 17 years) with Asthma
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Velsecorat (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Acronyms AMBER
- Sponsors AstraZeneca
Most Recent Events
- 19 May 2021 Results and learning from AMBER presented at the 117th International Conference of the American Thoracic Society
- 17 Aug 2020 Status changed from recruiting to completed.
- 20 May 2020 Trial design presented at the 116th International Conference of the American Thoracic Society